Oregon Medical Research Center
Portland, Oregon, 97223, United States
NCT Number: NCT00117923
The primary purpose of this study is to evaluate the effectiveness in adults of four different strengths of resiquimod gel applied to common wart(s) five times a week for four weeks.
A second purpose is to evaluate the safety of the drug.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Portland, Oregon, 97223, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Graceway Pharmaceuticals, LLC
Industry
A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02231879
Agammaglobulinemia, Agranulocytosis
Bethesda, Maryland, United States
View Trial DetailsNCT07329907
DNA Virus Infections, Human Papilloma Virus (HPV)
Banhā, Qalyubia Governorate, Egypt
View Trial DetailsNCT05087849
Communicable Diseases, Condyloma
San Francisco, California, United States
View Trial DetailsNCT05799157
Common Wart, DNA Virus Infections
Fort Smith, Arkansas, United States
View Trial Details